Breast cancer disparities at home and abroad: A review of the challenges and opportunities for system-level change

Clinical Cancer Research

Volumn 23, Issue 11, 2017, Pages 2655-2664

  Reeder Hayes, Katherine E ^a,b   Anderson, Benjamin O ^c,d  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CLINICAL AUDIT; EARLY CANCER DIAGNOSIS; EPIDEMIOLOGICAL DATA; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH DISPARITY; HEALTH INSURANCE; HIGH INCOME COUNTRY; HUMAN; LOW INCOME COUNTRY; MIDDLE INCOME COUNTRY; MINORITY GROUP; PATIENT CARE; PRIORITY JOURNAL; RACE DIFFERENCE; THERAPY DELAY; UNITED STATES; AFRICAN AMERICAN; ANCESTRY GROUP; BREAST TUMOR; CAUCASIAN; ECONOMICS; FEMALE; GENETICS; PATHOLOGY; RISK FACTOR;

AFRICAN AMERICANS; BREAST NEOPLASMS; CONTINENTAL POPULATION GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; RISK FACTORS; UNITED STATES;

EID: 85020316160     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-2630     Document Type: Article

References (105)

1. Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 2014;106. pii: dju055.
2. DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: convergence of incidence rates between black and white women. CA Cancer J Clin 2016;66:31-42.
3. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-502.
4. Chen VW, Correa P, Kurman RJ, Wu XC, Eley JW, Austin D, et al. Histological characteristics of breast carcinoma in blacks and whites. Cancer Epidemiol Biomarkers Prev 1994;3:127-35.
5. Porter PL, Lund MJ, Lin MG, Yuan X, Liff JM, Flagg EW, et al. Racial differences in the expression of cell cycle-regulatory proteins in breast carcinoma. Cancer 2004;100:2533-42.
6. Yates LR, Desmedt C. Translational genomics: practical applications of the genomic revolution in breast cancer. Clin Can Res 2017;23:2630-9.
7. Nik-Zainal S, Morganella S. Mutational signatures in breast cancer: the problem at the DNA level. Clin Can Res 2017;23:2617-29.
8. Troester MA, Sun X, Allot EH, Geradts J, Cohen SM, Tse CH, et al. Racial differences in PAM50 subtypes in the Carolina Breast Cancer Study. J Natl Cancer Inst. In press.
9. Curtis E, Quale C, Haggstrom D, Smith-Bindman R. Racial and ethnic differences in breast cancer survival: how much is explained by screening, tumor severity, biology, treatment, comorbidities, and demographics? Cancer 2008;112:171-80.
10. O'Brien KM, Cole SR, Tse CK, Perou CM, Carey LA, Foulkes WD, et al. Intrinsic breast tumor subtypes, race, and long-term survival in the Carolina Breast Cancer Study. Clin Cancer Res 2010;16:6100-10.
11. Phelan JC, Link BG, Tehranifar P. Social conditions as fundamental causes of health inequalities: theory, evidence, and policy implications. J Health Soc Behav 2010;51 Suppl:S28-40.
12. Vonderheide RH, Domchek SM, Clark AS. Immunotherapy for breast cancer: what are we missing? Clin Can Res 2017;23:2640-6.
13. Wheeler SB, Reeder-Hayes KE, Carey LA. Disparities in breast cancer treatment and outcomes: biological, social, and health system determinants and opportunities for research. Oncologist 2013;18:986-93.
14. Hershman D, McBride R, Jacobson JS, Lamerato L, Roberts K, Grann VR, et al. Racial disparities in treatment and survival among women with early-stage breast cancer. J Clin Oncol 2005;23:6639-46.
15. Durham DD, Robinson WR, Lee SS, Wheeler SB, Reeder-Hayes KE, Bowling JM, et al. Insurance-based differences in time to diagnostic follow-up after positive screening mammography. Cancer Epidemiol Biomarkers Prev 2016;25:1474-82.
16. Halpern MT, Schrag D. Effects of state-level medicaid policies and patient characteristics on time to breast cancer surgery among Medicaid beneficiaries. Breast Cancer Res Treat 2016;158:573-81.
17. George P, Chandwani S, Gabel M, Ambrosone CB, Rhoads G, Bandera EV, et al. Diagnosis and surgical delays in African American andwhite women with early-stage breast cancer. J Women's Health 2015;24:209-17.
18. Polverini AC, Nelson RA, Marcinkowski E, Jones VC, Lai L, Mortimer JE, et al. Time to treatment: measuring quality breast cancer care. Ann Surg Oncol 2016;23:3392-402.
19. Smith EC, Ziogas A, Anton-Culver H. Delay in surgical treatment and survival after breast cancer diagnosis in young women by race/ethnicity. JAMA Surg 2013;148:516-23.
20. Sheppard VB, Oppong BA, Hampton R, Snead F, Horton S, Hirpa F, et al. Disparities in breast cancer surgery delay: the lingering effect of race. Ann Surg Oncol 2015;22:2902-11.
21. Reeder-Hayes KE, Bainbridge J, Meyer AM, Amos KD, Weiner BJ, Godley PA, et al. Race and age disparities in receipt of sentinel lymph node biopsy for early-stage breast cancer. Breast Cancer Res Treat 2011;128:863-71.
22. Black DM, Jiang J, Kuerer HM, Buchholz TA, Smith BD. Racial disparities in adoption of axillary sentinel lymph node biopsy and lymphedema risk in women with breast cancer. JAMA Surg 2014;149:788-96.
23. Carpenter WR, Reeder-Hayes K, Bainbridge J, Meyer AM, Amos KD, Weiner BJ, et al. The role of organizational affiliations and research networks in the diffusion of breast cancer treatment innovation. Med Care 2011;49:172-9.
24. Meyer AM, Reeder-Hayes KE, Liu H, Wheeler SB, Penn D, Weiner BJ, et al. Differential receipt of sentinel lymph node biopsy within practice-based research networks. Med Care 2013;51:812-8.
25. Alderman AK, Hawley ST, Janz NK, Mujahid MS, Morrow M, Hamilton AS, et al. Racial and ethnic disparities in the use of postmastectomy breast reconstruction: results from a population-based study. J Clin Oncol 2009;27:5325-30.
26. Freedman RA, Kouri EM, West DW, Keating NL. Racial/ethnic differences in patients' selection of surgeons and hospitals for breast cancer surgery. JAMA Oncol 2015;1:222-30.
27. Wheeler SB, Carpenter WR, Peppercorn J, Schenck AP, Weinberger M, Biddle AK. Structural/organizational characteristics of health services partly explain racial variation in timeliness of radiation therapy among elderly breast cancer patients. Breast Cancer Res Treat 2012;133:333-45.
28. Keating NL, Kouri E, He Y, Weeks JC, Winer EP. Racial differences in definitive breast cancer therapy in older women: are they explained by the hospitals where patients undergo surgery? Med Care 2009;47:765-73.
29. Parise CA, Bauer KR, Caggiano V. Disparities in receipt of adjuvant radiation therapy after breast-conserving surgery among the cancerreporting regions of California. Cancer 2012;118:2516-24.
30. Royak-Schaler R, Pelser C, Langenberg P, Hayes J, Gardner L, Nesbitt K, et al. Characteristics associated with the initiation of radiation therapy after breast-conserving surgery among African American and white women diagnosed with early-stage breast cancer in Maryland, 2000-2006. Ann Epidemiol 2012;22:28-36.
31. Griggs JJ, Hawley ST, Graff JJ, Hamilton AS, Jagsi R, Janz NK, et al. Factors associated with receipt of breast cancer adjuvant chemotherapy in a diverse population-based sample. J Clin Oncol 2012;30:3058-64.
32. Chavez-MacGregor M, Clarke CA, Lichtensztajn DY, Giordano SH. Delayed initiation of adjuvant chemotherapy among patients with breast cancer. JAMA Oncol 2016;2:322-9.
33. Nurgalieva ZZ, Franzini L, Morgan RO, Vernon SW, Liu CC, Du XL. Impact of timing of adjuvant chemotherapy initiation and completion after surgery on racial disparities in survival among women with breast cancer. Med Oncol 2013;30:419.
34. Griggs JJ, Sorbero ME, Stark AT, Heininger SE, Dick AW. Racial disparity in the dose and dose intensity of breast cancer adjuvant chemotherapy. Breast Cancer Res Treat 2003;81:21-31.
35. Griggs JJ, Culakova E, Sorbero ME, Poniewierski MS, Wolff DA, Crawford J, et al. Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol 2007;25:2522-7.
36. Freedman RA, Partridge AH. Emerging data and current challenges for young, old, obese, or male patients with breast cancer. Clin Can Res 2017;23:2647-54.
37. Freedman RA, Vaz-Luis I, Barry WT, Lii H, Lin NU, Winer EP, et al. Patterns of chemotherapy, toxicity, and short-term outcomes for older women receiving adjuvant trastuzumab-based therapy. Breast Cancer Res Treat 2014;145:491-501.
38. Reeder-Hayes K, Peacock Hinton S, Meng K, Carey LA, Dusetzina SB. Disparities in use of human epidermal growth hormone receptor 2-targeted therapy for early-stage breast cancer. J Clin Oncol 2016;34:2003-9.
39. Freedman RA, Hughes ME, Ottesen RA, Weeks JC, He Y, Wong YN, et al. Use of adjuvant trastuzumab in women with human epidermal growth factor receptor 2 (HER2)-positive breast cancer by race/ethnicity and education within the National Comprehensive Cancer Network. Cancer 2013;119:839-46.
40. Reeder-Hayes K, Meyer A-M, Dusetzina S, Liu H, Wheeler SB. Racial disparities in initiation of endocrine therapy for early-stage breast cancer. J Clin Oncol 31, 2013 (suppl; abstr 6572).
41. Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8, 769 early-stage breast cancer patients. JClin Oncol 2010;28:4120-8.
42. Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 2003;21:602-6.
43. Roberts MC, Wheeler SB, Reeder-Hayes K. Racial/ethnic and socioeconomic disparities in endocrine therapy adherence in breast cancer: a systematic review. Am J Public Health 2015;105 Suppl 3:e4-e15.
44. Hershman DL, Tsui J, Meyer J, Glied S, Hillyer GC, Wright JD, et al. The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer. J Natl Cancer Inst 2014;106. pii: dju319.
45. Neugut AI, Subar M, Wilde ET, Stratton S, Brouse CH, Hillyer GC, et al. Association between prescription co-payment amount and compliance with adjuvant hormonal therapy in womenwith early-stage breast cancer. J Clin Oncol 2011;29:2534-42.
46. Neuner JM, Kamaraju S, Charlson JA, Wozniak EM, Smith EC, Biggers A, et al. The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees. J Natl Cancer Inst 2015;107.
47. Institute of Medicine (US) Committee on Understanding and Eliminating Racial and Ethnic Disparities in Health Care; Smedley BD, Stith AY, Nelson AR, editors. Unequal treatment: confronting racial and ethnic disparities in health care. Washington (DC): National Academies Press (US); 2003.
48. McGuire TG, Alegria M, Cook BL, Wells KB, Zaslavsky AM. Implementing the institute of medicine definition of disparities: an application to mental health care. Health Serv Res 2006;41:1979-2005.
49. Cook BL, McGuire TG, Zaslavsky AM. Measuring racial/ethnic disparities in health care: methods and practical issues. Health Serv Res 2012;47(3 Pt 2):1232-54.
50. Miller JW, Hanson V, Johnson GD, Royalty JE, Richardson LC. From cancer screening to treatment: service delivery and referral in the National Breast and Cervical Cancer Early Detection Program. Cancer 2014;120 Suppl 16:2549-56.
51. Howard DH, Ekwueme DU, Gardner JG, Tangka FK, Li C, Miller JW. The impact of a national program to provide free mammograms to lowincome, uninsured women on breast cancer mortality rates. Cancer 2010;116:4456-62.
52. Courtemanche C, Marton J, Ukert B, Yelowitz A, Zapata D. Early impacts of the affordable care act on health insurance coverage in medicaid expansion and non-expansion states. J Policy Anal Manage 2017;36:178-210.
53. Kehl KL, Liao KP, Krause TM, Giordano SH. Access to accredited cancer hospitals within federal exchange plans under the affordable care act. J Clin Oncol 2017;35:645-51.
54. Battaglia TA, Darnell JS, Ko N, Snyder F, Paskett ED, Wells KJ, et al. The impact of patient navigation on the delivery of diagnostic breast cancer care in the National Patient Navigation Research Program: a prospective meta-analysis. Breast Cancer Res Treat 2016;158:523-34.
55. Rocque GB, Partridge EE, Pisu M, Martin MY, Demark-Wahnefried W, Acemgil A, et al. The patient care connect program: transforming health care through lay navigation. J Oncol Pract 2016;12:e633-42.
56. Meade CD, Wells KJ, Arevalo M, Calcano ER, Rivera M, Sarmiento Y, et al. Lay navigator model for impacting cancer health disparities. J Cancer Educ 2014;29:449-57.
57. Steinberg ML, Fremont A, Khan DC, Huang D, Knapp H, Karaman D, et al. Lay patient navigator program implementation for equal access to cancer care and clinical trials: essential steps and initial challenges. Cancer 2006;107:2669-77.
58. Rocque GB, Pisu M, Jackson BE, Kvale EA, Demark-Wahnefried W, Martin MY, et al. Resource use and medicare costs during lay navigation for geriatric patients with cancer. JAMA Oncol 2017 Jan 26. [Epub ahead of print].
59. Jean-Pierre P, Cheng Y, Wells KJ, Freund KM, Snyder FR, Fiscella K, et al. Satisfaction with cancer care among underserved racial-ethnic minorities and lower-income patients receiving patient navigation. Cancer 2016;122:1060-7.
60. Myers SN, Ghani KR, Dunn RL, Lane BR, Schervish EW, Gao Y, et al. Notable outcomes and trackable events after surgery: evaluating an uncomplicated recovery after radical prostatectomy. J Urol 2016;196:399-404.
61. Hurley P, Dhir A, Gao Y, Drabik B, Lim K, Curry J, et al. A statewide intervention improves appropriate imaging in localized prostate cancer. J Urol 2017;197:1222-8.
62. Dangi-Garimella S. QOPI, the ASCO initiative, improves compliance and promotes quality of patient care. AmJ Manag Care 2014;20(5 Spec No.):E1.
63. Hoverman JR, Klein I, Harrison DW, Hayes JE, Garey JS, Harrell R, et al. Opening the black box: the impact of an oncology management program consisting of level I pathways and an outbound nurse call system. J Oncol Pract 2014;10:63-7.
64. McAlearney AS, Murray K, Sieck C, Lin JJ, Bellacera B, Bickell NA. The challenge of improving breast cancer care coordination in safety-net hospitals: barriers, facilitators, and opportunities. Med Care 2016;54:147-54.
65. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. 2013 GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon (France): International Agency for Research on Cancer; 2017 [cited 2017 May 12]. Available from: http://globocan. iarc.fr.
66. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000;50:7-33.
67. DeSantis CE, Bray F, Ferlay J, Lortet-Tieulent J, Anderson BO, Jemal A. International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol Biomarkers Prev 2015;24:1495-506.
68. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
69. Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 2011;378:1461-84.
70. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
71. Kalager M, Zelen M, Langmark F, Adami HO. Effect of screening mammography on breast-cancer mortality in Norway. NEngl JMed 2010;363:1203-10.
72. Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002;347:1233-41.
73. Veronesi U, Cascinelli N, Mariani L, Greco M, Saccozzi R, Luini A, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002;347:1227-32.
74. Early Breast Cancer Trialists' Collaborative G, Darby S, McGale P, Correa C, Taylor C, Arriagada R, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10, 801 women in 17 randomised trials. Lancet 2011;378:1707-16.
75. Early Breast Cancer Trialists' Collaborative G, McGale P, Taylor C, Correa C, Cutter D, Duane F, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 2014;383:2127-35.
76. Early Breast Cancer Trialists' Collaborative G, Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-levelmetaanalysis of randomised trials. Lancet 2011;378:771-84.
77. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group [see comments]. Lancet 1998;351:1451-67.
78. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Dowsett M, Forbes JF, Bradley R, Ingle J, Aihara T, et al. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet 2015;386:1341-52.
79. Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Peto R, Davies C, Godwin J, Gray R, Pan HC, et al. Comparisons between different polychemotherapy regimens for early breast cancer: metaanalyses of long-term outcome among 100, 000 women in 123 randomised trials. Lancet 2012;379:432-44.
80. Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003;95:1276-99.
81. Broeders M, Moss S, Nystrom L, Njor S, Jonsson H, Paap E, et al. The impact of mammographic screening on breast cancer mortality in Europe: a review of observational studies. J Med Screen 2012;19 Suppl 1:14-25.
82. Njor S, Nystrom L, Moss S, Paci E, Broeders M, Segnan N, et al. Breast cancer mortality in mammographic screening in Europe: a review of incidencebased mortality studies. J Med Screen 2012;19 Suppl 1:33-41.
83. Paci E, Broeders M, Hofvind S, Puliti D, Duffy SW. European breast cancer service screening outcomes: a first balance sheet of the benefits and harms. Cancer Epidemiol Biomarkers Prev 2014;23:1159-63.
84. Anderson BO, Lipscomb J, Murillo RH, Thomas DB. Breast cancer. In: Gelband H, Jha P, Sankaranarayanan R, Horton S, editors. Cancer: disease control priorities. 3rd ed. Vol. 3. Washington (DC): The World Bank; 2015. p. 45-68.
85. Smith RA, Caleffi M, Albert US, Chen TH, Duffy SW, Franceschi D, et al. Breast cancer in limited-resource countries: early detection and access to care. Breast J 2006;12 Suppl 1:S16-26.
86. McPhail S, Johnson S, Greenberg D, Peake M, Rous B. Stage at diagnosis and early mortality from cancer in England. Br J Cancer 2015;112 Suppl 1:S108-15.
87. Elkin EB, Hudis C, Begg CB, Schrag D. The effect of changes in tumor size on breast carcinoma survival in the U. S.: 1975-1999. Cancer 2005;104:1149-57.
88. Independent UKPoBCS. The benefits and harms of breast cancer screening: an independent review. Lancet 2012;380:1778-86.
89. Lauby-Secretan B, Scoccianti C, Loomis D, Benbrahim-Tallaa L, Bouvard V, Bianchini F, et al. Breast-cancer screening-viewpoint of the IARC Working Group. N Engl J Med 2015;372:2353-8.
90. Mittra I, Mishra GA, Singh S, Aranke S, Notani P, Badwe R, et al. A cluster randomized, controlled trial of breast and cervix cancer screening in Mumbai, India: methodology and interim results after three rounds of screening. Int J Cancer 2010;126:976-84.
91. Sankaranarayanan R, Ramadas K, Thara S, Muwonge R, Prabhakar J, Augustine P, et al. Clinical breast examination: preliminary results from a cluster randomized controlled trial in India. J Natl Cancer Inst 2011;103:1476-80.
92. Miller AB, Wall C, Baines CJ, Sun P, To T, Narod SA. Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. Bmj 2014;348:g366.
93. Rajaraman P, Anderson BO, Basu P, Belinson JL, Cruz AD, Dhillon PK, et al. Recommendations for screening and early detection of common cancers in India. Lancet Oncol 2015;16:e352-61.
94. Guide to cancer early diagnosis. Geneva (Switzerland): World Health Organization; 2017 [cited 2017 May 9]. Available from: http://www.who.int/cancer/publications/cancer-early-diagnosis/en/.
95. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005;353:1784-92.
96. Slamon DJ, Eirmann W, Robert NJ, Giermek J, Martin M, Jasiowka M, et al. Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer [abstract]. In: Proceedings of the 38th Annual San Antonio Breast Cancer Symposium; 2015 Dec. 8-12; San Antonio, TX. San Antonio (TX): SABCS. Abstract nr S5-04.
97. Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, et al. Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 2008;9:730-56.
98. The World Bank. Health expenditure per capita (current US$). Washington (DC): The World Bank; 2017 [cited 2017 May 5]. Available from: http://data.worldbank.org/indicator/SH. XPD. PCAP?view=chart.
99. Farmer P, Frenk J, Knaul FM, Shulman LN, Alleyne G, Armstrong L, et al. Expansion of cancer care and control in countries of low and middle income: a call to action. Lancet 2010;376:1186-93.
100. United Nations General Assembly. Political declaration of the highlevel meeting of the general assembly on the prevention and control of non-communicable diseases (A/RES/66/2). New York: United Nations; 2011.
101. Bazargani YT, de Boer A, Schellens JH, Leufkens HG, Mantel-Teeuwisse AK. Essential medicines for breast cancer in low and middle income countries. BMC Cancer 2015;15:591.
102. Price AJ, Ndom P, Atenguena E, Mambou Nouemssi JP, Ryder RW. Cancer care challenges in developing countries. Cancer 2012;118:3627-35.
103. Anderson BO, Ilbawi AM, El Saghir NS. Breast cancer in low and middle income countries (LMICs): a shifting tide in global health. Breast J 2015;21:111-8.
104. Ilbawi AM, Anderson BO. Global cancer consortiums: moving from consensus to practice. Ann Surg Oncol 2015;22:719-27.
105. Anderson BO, Duggan C. Resource-stratified guidelines for cancer management: correction and commentary. J Global Oncol 2016;0:JGO006213.